US Pharma MarketingNovo Nordisk cans two more trials of IL-6 heart drug for futility
Novo Nordisk stops two more ziltivekimab heart trials, HERMES and ATHENA, after July Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA:…
Novo Nordisk has ended work early on two more late-stage studies of its IL-6 inhibitor ziltivekimab after the studies’ data monitoring committee determined there was little chance of them succeeding.
A spokesperson told Endpoints News ...
Source: Endpoints News